CuraGen Corp. and TopoTarget initiated a Phase I/II open-label, multi-center trial evaluating the efficacy and safety of intravenous belinostat (PXD101), an HDAC inhibitor, in combination with doxorubicin for the treatment of Soft Tissue Sarcomas (STS). During the initial dose escalation part of the trial, as many as 24 patients with solid tumors for whom no standard therapy exists will be enrolled in order to define the maximal tolerated dose (MTD) of belinostat in combination with doxorub...